EA201892354A1 - PHARMACEUTICAL COMPOSITION, CONTAINING β-BLOCKER, INHIBITOR TURNING ENZYME AND HYPOTENSIZING MEANS OR NPVS - Google Patents

PHARMACEUTICAL COMPOSITION, CONTAINING β-BLOCKER, INHIBITOR TURNING ENZYME AND HYPOTENSIZING MEANS OR NPVS

Info

Publication number
EA201892354A1
EA201892354A1 EA201892354A EA201892354A EA201892354A1 EA 201892354 A1 EA201892354 A1 EA 201892354A1 EA 201892354 A EA201892354 A EA 201892354A EA 201892354 A EA201892354 A EA 201892354A EA 201892354 A1 EA201892354 A1 EA 201892354A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blocker
hypotensizing
npvs
inhibitor
enzyme
Prior art date
Application number
EA201892354A
Other languages
Russian (ru)
Inventor
Жиль Фонкнехтен
Original Assignee
Ле Лаборатуар Сервье
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье filed Critical Ле Лаборатуар Сервье
Publication of EA201892354A1 publication Critical patent/EA201892354A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Фиксированные фармацевтические композиции, содержащие β-блокатор, бисопролол, гипотензивное средство, периндоприл и третье терапевтическое средство, применение указанной композиции для лечения и предотвращения сердечно-сосудистых заболеваний, в особенности артериальной гипертонии и стабильной ишемической болезни сердца. Лекарственные средства.Fixed pharmaceutical compositions containing β-blocker, bisoprolol, antihypertensive agent, perindopril and the third therapeutic agent, the use of this composition for the treatment and prevention of cardiovascular diseases, especially arterial hypertension and stable ischemic heart disease. Medicines.

EA201892354A 2016-04-20 2017-04-19 PHARMACEUTICAL COMPOSITION, CONTAINING β-BLOCKER, INHIBITOR TURNING ENZYME AND HYPOTENSIZING MEANS OR NPVS EA201892354A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1653502A FR3050380B1 (en) 2016-04-20 2016-04-20 PHARMACEUTICAL COMPOSITION COMPRISING A BETA-BLOCKER, A CONVERSION ENZYME INHIBITOR AND AN ANTIHYPERTENSOR OR NSAID.
PCT/FR2017/050929 WO2017182754A1 (en) 2016-04-20 2017-04-19 Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid

Publications (1)

Publication Number Publication Date
EA201892354A1 true EA201892354A1 (en) 2019-04-30

Family

ID=56943614

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892354A EA201892354A1 (en) 2016-04-20 2017-04-19 PHARMACEUTICAL COMPOSITION, CONTAINING β-BLOCKER, INHIBITOR TURNING ENZYME AND HYPOTENSIZING MEANS OR NPVS

Country Status (14)

Country Link
EP (1) EP3445342A1 (en)
KR (1) KR102267965B1 (en)
CN (1) CN109069438A (en)
BR (1) BR112018070968A2 (en)
EA (1) EA201892354A1 (en)
FR (1) FR3050380B1 (en)
GE (1) GEP20217310B (en)
MA (1) MA44728A (en)
PH (1) PH12018502155A1 (en)
RU (1) RU2756320C2 (en)
SG (2) SG10202009894PA (en)
TN (1) TN2018000344A1 (en)
UA (1) UA125511C2 (en)
WO (1) WO2017182754A1 (en)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645710C2 (en) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-aminopropanols, process for their manufacture and pharmaceutical preparation
FR2503155A2 (en) 1980-10-02 1982-10-08 Science Union & Cie NOVEL SUBSTITUTED IMINO DIACIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS AN ENZYME INHIBITOR
FR2620709B1 (en) 1987-09-17 1990-09-07 Adir PROCESS FOR THE INDUSTRIAL SYNTHESIS OF PERINDOPRIL AND ITS MAIN INTERMEDIATE SYNTHESIS
FR2807431B1 (en) 2000-04-06 2002-07-19 Adir NOVEL PROCESS FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
GB2361185A (en) * 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
AR036187A1 (en) 2001-07-24 2004-08-18 Adir A PROCESS FOR THE PREPARATION OF PERINDOPRIL, ANALOG COMPOUNDS AND ITS SALTS, INTERMEDIARY COMPOUND 2,5-DIOXO-OXAZOLIDINE AND PROCESS TO PREPARE A INTERMEDIARY
FR2827860B1 (en) 2001-07-24 2004-12-10 Servier Lab NOVEL PROCESS FOR SYNTHESIS OF ACID DERIVATIVES (2S, 3AS, 7AS) -1 - [(S) -ALANYL] -OCTAHYDRO-1H-INDOLE-2-CARBOXYLINE AND APPLICATION TO THE SYNTHESIS OF PERINDOPRIL
DE60220877T2 (en) 2002-01-30 2008-04-10 Les Laboratoires Servier Process for the preparation of high purity perindopril and intermediates useful in the synthesis
FR2838648B1 (en) 2002-04-18 2004-05-21 Servier Lab NEW PERINDOPRIL SALT AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EP1403275B1 (en) 2003-02-28 2005-10-19 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
ATE395913T1 (en) 2003-02-28 2008-06-15 Servier S A Lab METHOD FOR PRODUCING PERINDOPRIL
EP1321471B1 (en) 2003-03-12 2005-05-04 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
DK1367061T3 (en) 2003-06-30 2006-05-15 Servier Lab Process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
DE60313391T2 (en) 2003-06-30 2008-01-17 Les Laboratoires Servier Process for the synthesis of perindopril and its pharmaceutically acceptable salts
AU2004261212B2 (en) * 2003-07-28 2011-01-27 Dr. Reddy's Laboratories Ltd. Treatment and prevention of cardiovascular events
ATE337332T1 (en) 2003-07-31 2006-09-15 Servier Lab METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
ATE338058T1 (en) 2003-07-31 2006-09-15 Servier Lab METHOD FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
EP1380591B1 (en) 2003-08-29 2005-11-16 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
PT1380590E (en) 2003-08-29 2006-12-29 Servier Lab Method for synthesis of perindopril and its pharmaceutically acceptable salts
ES2250853T3 (en) 2003-08-29 2006-04-16 Les Laboratoires Servier PROCEDURE FOR THE SYNTHESIS OF PERINDOPRIL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS.
SI1420028T1 (en) 2003-11-19 2007-06-30 Servier Lab Method for synthesis of perindopril and its pharmaceutically acceptable salts
PT1422236E (en) 2003-11-19 2007-05-31 Servier Lab Method for synthesis of perindopril and its pharmaceutically acceptable salts
EP1420029B9 (en) 2003-12-10 2008-11-12 Les Laboratoires Servier Method for synthesis of perindopril and its pharmaceutically acceptable salts
SI21800A (en) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
FR2894825B1 (en) 2005-12-21 2010-12-03 Servier Lab NOVEL ASSOCIATION OF SINUSAL IF CURRENT INHIBITOR AND CONVERSION ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2897866B1 (en) 2006-02-28 2008-04-18 Servier Lab ALPHA CRYSTALLINE FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2897865B1 (en) 2006-02-28 2008-04-18 Servier Lab BETA CRYSTALLINE SHAPE OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
CN101024082A (en) * 2007-04-06 2007-08-29 张士东 Compounded medicine for wholely preventing and treating cardio-cerebral blood vessel diseases and use thereof
DK2318365T3 (en) 2008-06-24 2015-11-23 Mylan Lab Ltd NOVEL polymorphic forms of perindopril (L) -arginine AND PROCESS FOR PREPARATION THEREOF
HU230877B1 (en) 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stable pharmaceutical combination
CA2754134C (en) * 2009-02-11 2018-09-18 Cadila Pharmaceuticals Ltd. Stable pharmaceutical composition for atherosclerosis
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
FR2961105B1 (en) 2010-06-15 2013-02-08 Servier Lab USE OF THE ASSOCIATION OF A SINUSAL IF CURRENT INHIBITOR AND AN INHIBITOR OF THE ANGIOTENSIN CONVERSION ENZYME FOR THE TREATMENT OF CARDIAC INSUFFICIENCY
FR2985511B1 (en) 2012-01-05 2014-01-03 Servier Lab CRYSTALLINE DELTA FORM OF PERINOPRIL ARGININE SALT, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Also Published As

Publication number Publication date
KR20180132911A (en) 2018-12-12
FR3050380B1 (en) 2020-07-10
TN2018000344A1 (en) 2020-06-15
UA125511C2 (en) 2022-04-13
RU2756320C2 (en) 2021-09-29
SG10202009894PA (en) 2020-11-27
CN109069438A (en) 2018-12-21
RU2018140193A (en) 2020-05-20
BR112018070968A2 (en) 2019-01-29
MA44728A (en) 2019-02-27
KR102267965B1 (en) 2021-06-21
SG11201808848SA (en) 2018-11-29
FR3050380A1 (en) 2017-10-27
PH12018502155A1 (en) 2019-07-15
RU2018140193A3 (en) 2020-06-03
GEP20217310B (en) 2021-11-10
EP3445342A1 (en) 2019-02-27
WO2017182754A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CY1123810T1 (en) TRIFLUOROMETHYL SUBSTITUTED PYRAZOLES AS KALLIKREIN INHIBITORS IN HUMAN PLASMA
CY1124084T1 (en) AMIDE SUBSTITUTED PYRIDINYLTRIAZOLE DERIVATIVES AND USES THEREOF
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201170531A1 (en) COMPOUNDS BASED ON Pyridine and Pyrimidine as WNT Signal Inhibitors for Cancer Treatment
EA201270215A1 (en) APAF-1 INHIBITOR COMPOUNDS
PH12018502016A1 (en) Substituted indole derivatives as dengue viral replication inhibitors
PH12018502077A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
CY1124907T1 (en) KALLIKREIN INHIBITORS IN HUMAN PLASMA
EA201792341A1 (en) DERIVATIVES OF PYRAZOLA SUITABLE AS INHIBITOR PROTEINS ACTIVATING 5-LIPOXYGENASE (FLAP)
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
EA202091003A1 (en) NEW PYRAZOLOPYROLOPYRIMIDINEDIONE DERIVATIVES AS P2X3 INHIBITORS
MA32224B1 (en) (Pyrazolyl-carbonyl) imidazolidinone derivatives for the treatment of retroviral diseases
PH12017501668A1 (en) Bace1 inhibitors
EA201990947A1 (en) SUBSTITUTED DERIVATIVES 6- (1H-PYRAZOL-1-IL) PYRIMIDIN-4-AMINE AND THEIR APPLICATION
EA201892354A1 (en) PHARMACEUTICAL COMPOSITION, CONTAINING β-BLOCKER, INHIBITOR TURNING ENZYME AND HYPOTENSIZING MEANS OR NPVS
EA202090165A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES ASSOCIATED WITH DIABETES, CONTAINING AMLODIPINE, LOSARTAN AND ROSUVASTATIN, AND PREPARATION
EA202090666A1 (en) APPLICATION OF BENZOATE-CONTAINING COMPOSITION FOR TREATMENT OF GLYCINE ENCEPHALOPATHY
EA201790772A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BETA-BLOCKER AND INHIBITOR ANGIOTENZIN-CONVERTING ENZYME
EA201991746A1 (en) PYRAZOLE DERIVATIVES AS BROMODOMENE INHIBITORS
EA202192544A1 (en) NEW POTASSIUM CHANNEL INHIBITORS
MX2023005913A (en) Benzenesulfonamide derivatives and uses thereof.